BioAlliance Pharma suspends Phase II liver cancer trial

The company is following advice provided by the drug safety monitoring board and the steering committee, which have been continuously monitoring the trial’s progress.

On the basis of the initial data, the two committees observed a clinical benefit but also more frequent and more severe pulmonary adverse events than expected and have thus recommended suspension of the trial, given the incidence of this type of effect.

This type of acute pulmonary damage was observed in Phase I/II trial at a dose of 35mg/m2 (the maximum tolerated dose) but had not been observed at 30mg/m2, the dose chosen for repeated administrations in the next development phase.

In this Phase II trial, doxorubicin Transdrug was being compared with the current standard of care (a control group undergoing trans-arterial chemo-embolization). In terms of the criteria for assessing the efficacy and safety of repeated intra-arterial hepatic injection of doxorubicin Transdrug, the efficacy endpoint was based on progression-free survival after three months of treatment.

Dominique Costantini, BioAlliance Pharma’s co-founder, president and CEO, said: “Our product portfolio is based on independent innovations, and each has its own risks. This allows us to redirect our focus so if this trial has to be suspended permanently, we shall bring another compound into the clinical phase.”